We are TAE Life Sciences
Mission
Vision
Our Leadership Team
Bruce Bauer, PhD
Chief Executive Officer
Robert Hill
Chief Operating Officer
Kendall Morrison, PhD
Chief Science Officer
Anna Theriault
Head of Global Product Strategy and Marketing
Robert Kirby
Vice President of Regulatory Affairs
Chad Lee, PhD
Director of Clinical Development
Barry Bonner
Vice President of Business Development, Americas
Arnold Dijkstra
Vice President of Business Development, EMEAOur Board of Directors
Bruce Bauer, PhD
Chief Executive Officer, TAE Life Sciences
Michl Binderbauer, PhD
Chief Executive Officer, TAE Technologies, Inc.
Stuart Peterson
Co-Founder and President, ARTIS Ventures
Artem Smirnov, PhD
Chief Technology Officer, TAE Technologies, Inc.Partners
Clinical Partners
A New Modality in Cancer Treatment
BNCT is vastly different approach to radiotherapy and TAE Life Sciences is dedicated to thorough clinical investigation and validation of BNCT as a new treatment modality.
We are seeking institutional partners to conduct the necessary research and clinical trials using our proprietary BNCT platform to establish efficacy and regulatory approval. Expanding your treatment options to offer hope patients who can benefit from the research we do together.
Fits Within Your Hospital
Business Partners
TAE Life Sciences has established and exclusive partnership for the Chinese market with Neuboron Medtech Ltd. to exclusively provide our neutron beam system. Neuboron is the first high-tech company in China to focus on delivering a full range of solution for accelerator-based BNCT.
FAQ
TAE Life Sciences (TLS) is medical equipment and biotechnology company, spun off from TAE Technologies (TAE), a global pioneer in fusion energy research. TAE has invested over $75 million in R&D on beam technology and are a significant shareholder of TAE Life Sciences and hold seats on the Board of Directors.
Technology developed by TAE, including its accelerator-based neutron source, has been adapted and validated as a neutron irradiation system (NIS) for medical use. TLS was formed to realize a novel cellular-targeted cancer treatment (CTRT), based on Boron Neutron Capture Therapy (BNCT), which currently is only available for medical research, and make it more widely available as a new cancer therapy.
TLS was launched in 2017 and is headquartered in Foothill Ranch, CA.
Our team has spent their careers in medical technology innovation, global business development, marketing, sales and financing in both early and late stage healthcare, radiation oncology, and biotechnology companies. We have global leading scientists with particle experience. We have medical device industry leaders who have broad regulatory, quality and engineering experience. Our venture backers, including ARTIS Ventures, have a deep history of financing medical technology companies.
We have raised $40m in venture capital to date. Our Series A round closed in 2017, led by ARTIS Ventures, a VC group out of San Francisco with significant success in biotechnology.
China is a strategic radiotherapy growth market and has a 5x greater incidence of head and neck cancers, which BNCT research has shown more favorable outcomes compared with other treatments. TLS has secured a Joint Venture with NeuboronMedTech, a Chinese radiotherapy company founded by Prof. Yuan Liu, one of the global leading BNCT experts.
BNCT is a targeted, non-invasive, two-step procedure designed to treat the most difficult and inoperable cancers. A patient is first infused with a non-toxic boron-10 compound, which preferentially accumulates in tumor tissue. After the infusion, the tumor is irradiated with low energy neutrons. The cells that have absorbed boron generate lithium ions and alpha particles that damage the cellular DNA and destroy cancer cells from the inside. As a result, there is minimized harm to surrounding healthy tissue not containing boron.
BNCT is radically different from other radiation delivery techniques because it is combined with the precision and accuracy of target drugs to kill cancer at the cellular level.
- Traditional radiation using photons passes through the tumor in the body and deposits considerable amounts of energy in healthy tissue. There are also tumors that are radiosensitive or do not respond well to photon/x-ray-based radiation therapy and therefore provide poor quality outcomes for patients.
- Newer particle radiation technology such as proton therapy have limited clinical evidence and have the potential to over dose or under dose the tumor, which could impact patients’ quality of life. These systems also have a much higher total cost of ownership.
- BNCT uses a target drug containing boron-10 which is selectively absorbed by the cancer cells, and when irradiated with a neutron beam, initiates a reaction that emits, high-energy charged particles which have shown to systemically destroy the cancer cells with little damage to the healthy tissue.
- BNCT does not require strict immobilization of the patient or sub-millimeter patient positioning accuracy for treatment because the target accuracy is provided by the drug.